Company
Allergy Therapeutics PLC
LON:AGY
Allergy Therapeutics PLC is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
298 stories · page 1 of 3
Archive
Small Cap Feast - Allergy Therapeutics, Crossword Cybersecurity, and more...
19 April 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners: No joiners today.Leavers: No leavers today.What’s cooking in the IPO kitchen?**Golden Metal Resources Plc (PR
Small Cap Feast - Allergy Therapeutics, Belvoir Group, Coro Energy, and more...
27 March 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**LON:BCE, intends to join the AIM
Allergy Therapeutics to suspend shares after accounts delay
"Shares of the company will be suspended from trading from 7.30 am on 3 January 2023"
Allergy Therapeutics plans for UK manufacturing site restart is "welcome news" says finnCap
The finnCap analysts said: "While its competitors will no doubt take advantage of this hiatus, we think it will be a FY 2023 event only and, to that extent, leave FY 2024 forecasts unchanged"
Allergy Therapeutics to resume UK production in mid-November
AIM-quoted biotech company voluntarily paused production following an internal review
Allergy Therapeutics CEO: Temporary production pause will help build capacity for future growth
"This temporary pausing of production is a necessary step to ensure that we can both continue to deliver the highest standards of quality in our products and build capacity for the future growth of the group,” said chief executive Manuel Ll
Allergy Therapeutics raises funds as it gears up for the start of two key clinical trials
The fund raising is supported by a number of the company's largest shareholders and the proceeds will help fund the group's Phase I peanut trial and Grass Phase III trial
Allergy Therapeutics looks ahead to start of clinical trials
The hay fever and vaccine specialist said revenues for the year to June 2022 will be £72.8mln
Allergy Therapeutics to present 18 posters at EAACI conference
“Our latest findings pave the way for the initiation of two key clinical trials later this year," said chief executive Manuel Llobet
Allergy Therapeutics says CFO to leave
Nick Wykeman will depart in six months after six successful years with the business
Allergy Therapeutics to present new data on lead vaccines this week
Data from its grass pollen jab field study showed clinically relevant and statistically significant reductions in daily symptoms
Allergy Therapeutics primed for a pivotal year
Our company continues to stand out as a high-value hybrid, with its strong commercial business and high science R&D programmes," said chief executive Manuel Llobet
Allergy Therapeutics posts improved results from hay fever study
An improvement in symptoms of 39.5% was recorded gainst 36.8% previously
Allergy Therapeutics lands new £10mln financing facility
The new facility will run for up to five years and provides greater security.
Allergy Therapeutics shares up 9% after it gets the FDA green light to begin phase I peanut allergy trial
Top-line data from the study are expected in the first half of next year, earlier than the originally intended readout
Allergy Therapeutics update contains positive aspects on the trials front
House broker finnCap left its target price of 65p unchanged following the half-year results.
Allergy Therapeutics primed for clinical progress; 2022 to be 'pivotal year'
The company is kicking on with work on key treatments for grass pollen and peanut allergies
Allergy Therapeutics hails positive results from field trial of its short-course grass pollen immunotherapy
The treatment led to a “clinically relevant improvement” symptoms, investors were told
Allergy Therapeutics looks forward to multiple inflection points in coming year
Next major milestones include results from the grass field trial in the autumn and a meeting with the US drug regulator for VLP Peanut ahead of the expected start of its peanut allergy study next year
Allergy Therapeutics says new allergy treatment wins German 'Most Innovative Product 2021' award
ImmunoBON was voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards
Allergy Therapeutics hails encouraging secondary endpoint results from peanut allergy vaccine study
"These results provide strong confidence in the beneficial immunologic mode of action of VLP Peanut”
FTSE 100 closes lower amid disappointing US jobs number and ahead of US Labor Day long weekend
The UK's premier share index finished down on Friday around 25 points, or 0.36%, at 7,138
Archive
US non-farm payroll additions being revised down after ADP payrolls shocker
The first Friday of the month means the US jobs report covering the preceding month. Wednesday's ADP payrolls report came in well short of expectations but it is rarely a reliable guide to the official figures
Allergy Therapeutics' peanut vaccine study further de-risks programme says broker
"There is substantial potential upside as VLP Peanut progresses through the clinic"
Allergy Therapeutics announces successful primary outcome of VLP Peanut 001 study
The findings support the VLP Peanut first-in-human Phase I study design, which is on track to start in the first quarter of next year
Allergy Therapeutics sees revenue and operating profit ahead of expectations
In the latest update, it told investors revenues, with an 8% rise to £84.3mln for the 12 months to June 30, would beat forecasts
Allergy Therapeutics showcases latest advances
Chief executive Manuel Llobet said: “Our research programmes are going beyond symptom management, to focus on directly treating the cause of allergy"
Allergy Therapeutics ends financial year on a high with operating profits 'well ahead' of expectations
Looking ahead, net sales for 2022 are expected to grow at low single-digit levels
Allergy Therapeutics sets up for big year as convenience factor proves a winner
Its Pollinex Quatro platform comprises four to six jabs, against up to 15 for rival injections
Allergy Therapeutics hails conclusion of 'breakthrough' hay fever field study
Results are due in the second half and will be used to design the company's phase III trial of Grass MATA MPL
Allergy Therapeutics makes strong start to financial year unimpeded by lockdown and Brexit
Allergy cited top-line momentum and operational efficiency for the strong growth in profitability
Allergy Therapeutics sees record cash balance as interim sales rise 7%
Allergy says it is fully funded for two crucial upcoming clinical trials from its own resources
Allergy Therapeutics says peanut allergy biomarker study gets underway
The work is being carried out by researchers from Imperial College London
Allergy Therapeutics agrees refinancing package
Allergy Therapeutics PLC, which is headquartered in Worthing, West Sussex and employs around 500 people, develops inoculations against common allergies
Allergy Therapeutics says patient screening for exploratory field study of short-course grass allergy immunotherapy has begun
"This exploratory grass trial will drive study design innovation in the allergy field and is an important intermediate step for the optimisation of our upcoming pivotal phase III grass field trial, which will maximise the chances of success
Allergy Therapeutics sees growth across Europe as new trials approach
Bee sting treatment Venomil continued to grow very strongly, said Allergy
Allergy Therapeutics broadens its collaboration with vaccine pair in a deal that takes it into oncology
The company is currently developing a peanut allergy inoculation based on technology pioneered by Saiba and DeepVax
Allergy Therapeutics earnings to exceed expectations after a strong year
Net revenues for the 12 months ended June 30 were £78.2mln, up 6% year-on-year
Allergy Therapeutics allowed to hit the reset button on birch pollen phase III trial
“We remain committed to Birch MATA MPL, especially considering the results of the independent secondary endpoint data and the supportive safety profile observed in the B301 study and two successful phase II trials showing significant primar
Allergy Therapeutics gets big forecast upgrade from finncap after trading update
The broker now expects profits to around £5m higher than its previous forecasts at £2.9m.
Allergy Therapeutics says 2020 net profit will be well ahead of expectations
The update was provided in a brief trading statement
Allergy Therapeutics welcomes academic paper's endorsement of adjuvant technology
“We have developed biodegradable adjuvants that make allergy treatment more efficient than ever - a key technology in our pioneering approach to the development of innovative treatments for allergy patients"
Allergy Therapeutics hails "steady" first half performance; finnCap ups forecasts
The company ended the half-way period in a strong cash position with just under £40mln in the bank
Allergy Therapeutics: Journal article flags up potential of peanut vaccine
The data from the firm’s early-stage study was carried in The Journal of Allergy and Clinical Immunology
Allergy Therapeutics sees sales grow in all countries
Revenues rose by 9% in the six months to December to £50.5mln
Allergy Therapeutics opts to split phase III grass allergy study over two pollen seasons
It has done so after consulting experts and taking on board feedback from its phase III Birch MATA MPL trial
Allergy Therapeutics enjoys a strong and profitable year
The vaccines specialist weighed in with an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of £11.3mln, up 22%
Archive
FTSE 100 closes almost flat as US stocks rally on Trump trade war optimism
At the close, the UK blue chip index was only 1.44 points lower at 7.282.99, just off the late peak of 7,292.00 and well above the session low
Archive
Proactive news snapshot: Hurricane Energy PLC , Allergy Therapeutics, Polarean Imaging, Benchmark Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Attis surges after increasing production levels
A look at the day's major movers, including GCM, Alexander Mining, Jubilee Metals, McBride, Sosandar and Tekcapital
Allergy Therapeutics continues to trade ahead of expectations as it makes market share gains
In a comprehensive update on trading, the group said net revenue for the year is expected to be £73.7mln, up 8% on last year, while cash at the end of June was £27.4mln
Investments and investor services
FTSE 100 closes lower again as European shares slide as mood sours
Footsie closed on Thursday nearly 21 points lower at 7,509.
Archive
Proactive news snapshot: Richland Resources, Kromek, Powerhouse Energy, Allergy Therapeutics …
A glance at some of the day's highlights from the Proactive Investors newswire